1. PubMed Results
Items 1 -53 of 53 (Display the 53 citations in PubMed)
1. Cervical cancer control in India: taking evidence to action.
Farooqui HH, Zodpey S.
J Public Health Policy. 2012 May;33(2):165-72. doi: 10.1057/jphp.2012.7.
Review.
PMID: 22555096 [PubMed - indexed for MEDLINE]
Related citations
2. Cost and effectiveness evaluation of prophylactic HPV vaccine in developing
countries.
Termrungruanglert W, Havanond P, Khemapech N, Lertmaharit S,
Pongpanich S, Khorprasert C, Taneepanichskul S.
Value Health. 2012 Jan-Feb;15(1 Suppl):S29-34.
PMID: 22265063 [PubMed - indexed for MEDLINE]
Related citations
3. Impact of vaccine protection against multiple HPV types on the cost-
effectiveness of cervical screening.
Coupé VM, Bogaards JA, Meijer CJ, Berkhof J.
Vaccine. 2012 Feb 27;30(10):1813-22. Epub 2012 Jan 10.
PMID: 22240341 [PubMed - indexed for MEDLINE]
Related citations
4. Global human papillomavirus vaccination: can it be cost-effective?
Crosbie EJ.
BJOG. 2012 Jan;119(2):125-8. doi: 10.1111/j.1471-0528.2011.03090.x. No
abstract available.
PMID: 22168760 [PubMed - indexed for MEDLINE]
Related citations
5. Health economics of screening for gynaecological cancers.
Kulasingam S, Havrilesky L.
Best Pract Res Clin Obstet Gynaecol. 2012 Apr;26(2):163-73. Epub 2011
Dec 3. Review.
PMID: 22138003 [PubMed - indexed for MEDLINE]
Related citations
6. [Cost-utility of the vaccine against the Human Papiloma Virus in Peruvian
women].
Gutiérrez-Aguado A.
Rev Peru Med Exp Salud Publica. 2011 Jul-Sep;28(3):416-25. Spanish.
PMID: 22086620 [PubMed - indexed for MEDLINE] Free Article
Related citations

2. 7. Time for change? An economic evaluation of integrated cervical screening
and HPV immunization programs in Canada.
Tully SP, Anonychuk AM, Sanchez DM, Galvani AP, Bauch CT.
Vaccine. 2012 Jan 5;30(2):425-35. Epub 2011 Nov 7.
PMID: 22075091 [PubMed - indexed for MEDLINE]
Related citations
8. The role of cost-effectiveness in U.S. vaccination policy.
Kim JJ.
N Engl J Med. 2011 Nov 10;365(19):1760-1. Epub 2011 Oct 19. No abstract
available.
PMID: 22010866 [PubMed - indexed for MEDLINE] Free Article
Related citations
9. The clinical benefit and cost-effectiveness of human papillomavirus
vaccination for adult women in the Netherlands.
Bogaards JA, Coupé VM, Meijer CJ, Berkhof J.
Vaccine. 2011 Nov 8;29(48):8929-36. Epub 2011 Sep 22.
PMID: 21945961 [PubMed - indexed for MEDLINE]
Related citations
10. Cost-effectiveness of a cervical screening program with human
papillomavirus vaccine.
Sopina E, Ashton T.
Int J Technol Assess Health Care. 2011 Oct;27(4):290-7. Epub 2011 Sep
22.
PMID: 21936972 [PubMed - indexed for MEDLINE]
Related citations
11. Economic evaluation of policy options for prevention and control of cervical
cancer in Thailand.
Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S,
Riewpaiboon A, Chichareon S, Ieumwananonthachai N,
Tangcharoensathien V.
Pharmacoeconomics. 2011 Sep;29(9):781-806. doi: 10.2165/11586560-
000000000-00000.
PMID: 21838332 [PubMed - indexed for MEDLINE]
Related citations
12. Introducing HPV vaccine and scaling up screening procedures to prevent
deaths from cervical cancer in Japan: a cost-effectiveness analysis.
Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, Taketani
Y.
BJOG. 2012 Jan;119(2):177-86. doi: 10.1111/j.1471-0528.2011.03036.x.
Epub 2011 Jul 28.
PMID: 21794070 [PubMed - indexed for MEDLINE]

3. Related citations
13. Cost utility analysis of human papilloma virus vaccination for females in
three different age groups: a medical economics analysis.
Wiwanitkit V.
Taiwan J Obstet Gynecol. 2011 Jun;50(2):225-6. No abstract available.
PMID: 21791314 [PubMed - indexed for MEDLINE]
Related citations
14. Until which age should women be vaccinated against HPV infection?
Recommendation based on cost-effectiveness analyses.
Westra TA, Rozenbaum MH, Rogoza RM, Nijman HW, Daemen T, Postma
MJ, Wilschut JC.
J Infect Dis. 2011 Aug 1;204(3):377-84.
PMID: 21742836 [PubMed - indexed for MEDLINE] Free Article
Related citations
15. Population effectiveness, not efficacy, should decide who gets vaccinated
against human papillomavirus via publicly funded programs.
Castle PE, Zhao FH.
J Infect Dis. 2011 Aug 1;204(3):335-7. No abstract available. Erratum in: J
Infect Dis. 2011 Oct 1;204(7):1149.
PMID: 21742829 [PubMed - indexed for MEDLINE] Free Article
Related citations
16. Health and economic impact of HPV 16/18 vaccination and cervical cancer
screening in Eastern Africa.
Campos NG, Kim JJ, Castle PE, Ortendahl JD, O'Shea M, Diaz M, Goldie
SJ.
Int J Cancer. 2012 Jun 1;130(11):2672-84. doi: 10.1002/ijc.26269. Epub
2011 Aug 24.
PMID: 21717458 [PubMed - indexed for MEDLINE]
Related citations
17. Cost-effectiveness analysis for Pap smear screening and human
papillomavirus DNA testing and vaccination.
Chen MK, Hung HF, Duffy S, Yen AM, Chen HH.
J Eval Clin Pract. 2011 Dec;17(6):1050-8. doi: 10.1111/j.1365-
2753.2010.01453.x. Epub 2011 Jun 16.
PMID: 21679279 [PubMed - indexed for MEDLINE]
Related citations
18. Cost-effectiveness of human papillomavirus vaccination and cervical cancer
screening in Thailand.
Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ.
BJOG. 2012 Jan;119(2):166-76. doi: 10.1111/j.1471-0528.2011.02974.x.
Epub 2011 Apr 12.

4. PMID: 21481160 [PubMed - indexed for MEDLINE]
Related citations
19. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
Lee VJ, Tay SK, Teoh YL, Tok MY.
BMC Public Health. 2011 Mar 31;11:203.
PMID: 21453537 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
20. HPV vaccination in France: uptake, costs and issues for the National Health
Insurance.
Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H.
Vaccine. 2011 Apr 27;29(19):3610-6. Epub 2011 Mar 5.
PMID: 21382486 [PubMed - indexed for MEDLINE]
Related citations
21. The role of optimal control in assessing the most cost-effective
implementation of a vaccination programme: HPV as a case study.
Brown VL, Jane White KA.
Math Biosci. 2011 Jun;231(2):126-34. Epub 2011 Mar 4.
PMID: 21377481 [PubMed - indexed for MEDLINE]
Related citations
22. Is human papillomavirus screening preferable to current policies in
vaccinated and unvaccinated women? A cost-effectiveness analysis.
Accetta G, Biggeri A, Carreras G, Lippi G, Carozzi FM, Confortini M, Zappa
M, Paci E.
J Med Screen. 2010;17(4):181-9.
PMID: 21258128 [PubMed - indexed for MEDLINE]
Related citations
23. Prevention of cervical cancer in rural China: evaluation of HPV vaccination
and primary HPV screening strategies.
Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, Chen JF,
Legood R, Smith MA, Nickson C, Qiao YL.
Vaccine. 2011 Mar 16;29(13):2487-94. Epub 2011 Jan 4.
PMID: 21211586 [PubMed - indexed for MEDLINE]
Related citations
24. Comparative cost-effectiveness of HPV vaccines in the prevention of
cervical cancer in Malaysia.
Ezat SW, Aljunid S.
Asian Pac J Cancer Prev. 2010;11(4):943-51.
PMID: 21133606 [PubMed - indexed for MEDLINE] Free Article
Related citations
25. A generally applicable cost-effectiveness model for the evaluation of

5. vaccines against cervical cancer.
Demarteau N, Detournay B, Tehard B, El Hasnaoui A, Standaert B.
Int J Public Health. 2011 Apr;56(2):153-62. Epub 2010 Nov 26.
PMID: 21110060 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
26. Cost and financing issues limit access to the HPV vaccine.
Muthumariappan M, Raj GA.
Asian Pac J Cancer Prev. 2010;11(2):573-4.
PMID: 20843155 [PubMed - indexed for MEDLINE] Free Article
Related citations
27. A brief history of economic evaluation for human papillomavirus vaccination
policy.
Beutels P, Jit M.
Sex Health. 2010 Sep;7(3):352-8.
PMID: 20719227 [PubMed - indexed for MEDLINE]
Related citations
28. Cost-effectiveness of human papillomavirus vaccination and screening in
Spain.
Diaz M, de Sanjose S, Ortendahl J, O'Shea M, Goldie SJ, Bosch FX, Kim
JJ.
Eur J Cancer. 2010 Nov;46(16):2973-85. Epub 2010 Jul 16.
PMID: 20638840 [PubMed - indexed for MEDLINE]
Related citations
29. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer
screening programme in Slovenia.
Obradovic M, Mrhar A, Kos M.
Eur J Public Health. 2010 Aug;20(4):415-21. Epub 2010 Jul 12.
PMID: 20624834 [PubMed - indexed for MEDLINE] Free Article
Related citations
30. Monitoring the coverage and impact of human papillomavirus vaccine -
report of WHO meeting, November 2009.
[No authors listed]
Wkly Epidemiol Rec. 2010 Jun 18;85(25):237-43. English, French. No
abstract available.
PMID: 20583384 [PubMed - indexed for MEDLINE] Free Article
Related citations
31. Prophylaxis of cervical cancer and related cervical disease: a review of the
cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP.
J Manag Care Pharm. 2010 Apr;16(3):217-30. Review.

6. PMID: 20331326 [PubMed - indexed for MEDLINE] Free Article
Related citations
32. The cost effectiveness of a quadrivalent human papillomavirus vaccine
(6/11/16/18) in Hungary.
Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH.
J Med Econ. 2010 Mar;13(1):110-8.
PMID: 20085477 [PubMed - indexed for MEDLINE]
Related citations
33. Cost-effectiveness of human papilloma virus vaccination in Iceland.
Oddsson K, Johannsson J, Asgeirsdottir TL, Gudnason T.
Acta Obstet Gynecol Scand. 2009;88(12):1411-6.
PMID: 19900074 [PubMed - indexed for MEDLINE]
Related citations
34. A cost-utility analysis of cervical cancer vaccination in preadolescent
Canadian females.
Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N.
BMC Public Health. 2009 Oct 31;9:401.
PMID: 19878578 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
35. Cost-effectiveness analysis of a quadrivalent human papilloma virus
vaccine in Mexico.
Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.
Arch Med Res. 2009 Aug;40(6):503-13.
PMID: 19853192 [PubMed - indexed for MEDLINE]
Related citations
36. The potential cost-effectiveness of adding a human papillomavirus vaccine
to the cervical cancer screening programme in South Africa.
Sinanovic E, Moodley J, Barone MA, Mall S, Cleary S, Harries J.
Vaccine. 2009 Oct 19;27(44):6196-202. Epub 2009 Aug 19. Erratum in:
Vaccine. 2010 Aug 9;28(35):5755.
PMID: 19698807 [PubMed - indexed for MEDLINE]
Related citations
37. Cost-effectiveness evaluation of a quadrivalent human papillomavirus
vaccine in Belgium.
Cleemput I, Thiry N.
Pharmacoeconomics. 2009;27(5):433; author reply 433-4. doi:
10.2165/00019053-200927050-00008. No abstract available.
PMID: 19586082 [PubMed - indexed for MEDLINE]
Related citations
38. Cost-effectiveness analysis of human papillomavirus vaccination in the

7. Netherlands.
de Kok IM, van Ballegooijen M, Habbema JD.
J Natl Cancer Inst. 2009 Aug 5;101(15):1083-92. Epub 2009 Jul 1.
PMID: 19571256 [PubMed - indexed for MEDLINE] Free Article
Related citations
39. Epidemiological and economic impact of human papillomavirus vaccines.
Jeurissen S, Makar A.
Int J Gynecol Cancer. 2009 May;19(4):761-71.
PMID: 19509585 [PubMed - indexed for MEDLINE]
Related citations
40. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not
forget about cervical cancer screening.
Thiry N, De Laet C, Hulstaert F, Neyt M, Huybrechts M, Cleemput I.
Int J Technol Assess Health Care. 2009 Apr;25(2):161-70.
PMID: 19366497 [PubMed - indexed for MEDLINE]
Related citations
41. Human papillomavirus vaccines. WHO position paper.
[No authors listed]
Wkly Epidemiol Rec. 2009 Apr 10;84(15):118-31. English, French. No
abstract available.
PMID: 19360985 [PubMed - indexed for MEDLINE] Free Article
Related citations
42. From India to the world--a better way to prevent cervical cancer.
Schiffman M, Wacholder S.
N Engl J Med. 2009 Apr 2;360(14):1453-5. No abstract available.
PMID: 19339726 [PubMed - indexed for MEDLINE] Free Article
Related citations
43. Effectiveness and cost effectiveness of human papillomavirus vaccine: a
systematic review.
Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G.
Pharmacoeconomics. 2009;27(2):127-47. doi: 10.2165/00019053-
200927020-00004. Review. Erratum in: Pharmacoeconomics.
2009;27(4):354.
PMID: 19254046 [PubMed - indexed for MEDLINE]
Related citations
44. HPV16/18 vaccination to prevent cervical cancer in The Netherlands:
model-based cost-effectiveness.
Coupé VM, van Ginkel J, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J.
Int J Cancer. 2009 Feb 15;124(4):970-8.

8. PMID: 19035448 [PubMed - indexed for MEDLINE]
Related citations
45. Human papillomavirus vaccines: a complex decision focused on cancer
prevention and cost-effectiveness.
Jenkins D.
Lancet Infect Dis. 2008 Oct;8(10):589. No abstract available.
PMID: 18922480 [PubMed - indexed for MEDLINE]
Related citations
46. Cost-effectiveness of HPV vaccination compared with Pap smear screening
on a national scale: a literature review.
Techakehakij W, Feldman RD.
Vaccine. 2008 Nov 18;26(49):6258-65. Epub 2008 Oct 1. Review.
PMID: 18835313 [PubMed - indexed for MEDLINE]
Related citations
47. Human papillomavirus vaccination--reasons for caution.
Haug CJ.
N Engl J Med. 2008 Aug 21;359(8):861-2. No abstract available.
PMID: 18716305 [PubMed - indexed for MEDLINE] Free Article
Related citations
48. Health and economic implications of HPV vaccination in the United States.
Kim JJ, Goldie SJ.
N Engl J Med. 2008 Aug 21;359(8):821-32.
PMID: 18716299 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
49. Economic evaluation of human papillomavirus vaccination in the United
Kingdom.
Jit M, Choi YH, Edmunds WJ.
BMJ. 2008 Jul 17;337:a769. doi: 10.1136/bmj.a769.
PMID: 18640957 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
50. Health and economic impact of HPV 16 and 18 vaccination and cervical
cancer screening in India.
Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, Goldie SJ.
Br J Cancer. 2008 Jul 22;99(2):230-8. Epub 2008 Jul 8.
PMID: 18612311 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
51. [Generalized cost-effectiveness of preventive interventions against cervical
cancer in Mexican women: results of a Markov model from the public sector
perspective].

9. Gutiérrez-Delgado C, Báez-Mendoza C, González-Pier E, de la Rosa AP,
Witlen R.
Salud Publica Mex. 2008 Mar-Apr;50(2):107-18. Spanish.
PMID: 18372991 [PubMed - indexed for MEDLINE] Free Article
Related citations
52. Cost-effectiveness of human papillomavirus vaccination in the United
States.
Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE.
Emerg Infect Dis. 2008 Feb;14(2):244-51.
PMID: 18258117 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
53. Cost-effectiveness analysis: should it be required for drug registration and
beyond?
Arnold RJ.
Drug Discov Today. 2007 Nov;12(21-22):960-5. Epub 2007 Oct 30.
PMID: 17993415 [PubMed - indexed for MEDLINE]
Related citations